Skip to content
Pharma Observatory a Scientist.com platform

Organization (Other)

Beijing Biotech

ClinicalTrials.gov lists Beijing Biotech as lead sponsor of 32 trials. It has 261 active development programs and 2 approved assets.

Other
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Disease areas Disease areas 51 Trials by start year as sponsor or collaborator Trials by start year as sponsor or collaborator 1 Active development programs Active development programs 261 Approved assets Approved assets 2 Latest dated events Latest dated events 32 Biomarker capability evidence Biomarker capability evidence 164 Disease areas Disease areas 51 Trials by start year as sponsor or collaborator Trials by start year as sponsor or collaborator 1 Active development programs Active development programs 261 Approved assets Approved assets 2 Latest dated events Latest dated events 32 Biomarker capability evidence Biomarker capability evidence 164

Rows recorded per section (log scale)

18 sections measured, none recorded

This page covers Beijing Biotech: 32 lead-sponsored trials and 0 legal-entity registrations.

Get the Beijing Biotech report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (51)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Recurrence 8
Neoplasm Metastasis 6
Lung Neoplasms 5
Ovarian Neoplasms 4
Breast Neoplasms 3

Showing 5 of 51 disease areas.

Start your 14-day trial Email me the first 50 disease areas as a PDF

Trials by start year as sponsor or collaborator (1)

Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 32

Forecast of the full-year count, planned starts included, not rows of this table: about 36 trials starting in 2026 and about 16 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 30 months from start to primary completion across 22 trials still running at the 2026-10-09 snapshot. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

Active development programs (261)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
Lymphodepleting Chemotherapy Neoplasm Metastasis Phase 1/2 4
Lymphodepleting Chemotherapy Lung Neoplasms Phase 1/2 4
CYCLOPHOSPHAMIDE Recurrence Phase 1/2 4
CYCLOPHOSPHAMIDE Ovarian Neoplasms Phase 1/2 3
CYCLOPHOSPHAMIDE Glioblastoma Phase 1/2 3

Showing 5 of 261 active programs.

Start your 14-day trial Email me the first 50 active programs as a PDF

Approved assets (2)

Shown in this order: max phase first.

Approved assets
Drug Trials
FLUDARABINE 18
CYCLOPHOSPHAMIDE 17

Latest dated events (32)

Shown in this order: newest first.

Latest dated events
Date Event Source
2026-03-02 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-03-02 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-03-02 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-03-02 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-03-02 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Showing 5 of 32 events.

Start your 14-day trial Email me all 32 events as a PDF

Biomarker capability evidence (164)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
ALB Trial sponsor Named in trial inclusion criteria
AR Trial sponsor Named in trial inclusion criteria
BRAF Trial sponsor Named in trial inclusion criteria
CD19 Trial sponsor Named in trial inclusion criteria
CD276 Trial sponsor Named in trial inclusion criteria

Showing 5 of 164 evidence rows.

Start your 14-day trial Email me the first 50 evidence rows as a PDF

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sponsor delivery record, journals published in, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.